Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02913612
Other study ID # Pro00068212
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 5, 2017
Est. completion date October 20, 2020

Study information

Verified date March 2024
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and efficacy of Timolol 0.25% and 0.5% doses.


Description:

Primary: Describe the efficacy of 0.25% and 0.5% topical timolol maleate Gel-forming solution (GFS) as assessed through Infantile Hemangioma (IH) changes in volume. Secondary: Describe the safety of topical timolol maleate GFS for treatment of IH.


Recruitment information / eligibility

Status Completed
Enrollment 105
Est. completion date October 20, 2020
Est. primary completion date October 20, 2020
Accepts healthy volunteers No
Gender All
Age group N/A to 84 Days
Eligibility Inclusion Criteria 1. Documented informed consent from legal guardian 2. 0-84 days postnatal age at time of first study dose or when enrolled into the non-intervention cohort. 3. Clinical diagnosis of superficial cutaneous or mucosal infantile hemangioma (must include all of the following): 1. Superficial lesion in the dermis 2. Thin <2 mm in thickness 3. Small >=5 cm at its longest dimension and <=10cm2 4. Involves skin or keratinized mucosa Exclusion Criteria 1. History of previous treatment with any pharmacologic or laser therapy for IH 2. Ongoing therapy with an oral beta blocker or oral corticosteroid (e.g., cardiac arrhythmia, adrenal insufficiency, upper airway obstruction, tetralogy of fallot (TOF), hypertension, reactive airways disease) 3. IH that requires systemic therapy (defined by dynamic complication scale >3) 4. IH of the non-keratinized mucosa 5. Infants with more than one hemangioma that requires therapy 6. Hemodynamically significant cardiovascular disease, as determined by the investigator 7. Known allergy to beta blockers or vehicle 8. Heart rate <100 beats per minute at screening visit 9. Known prenatal or postnatal diagnosis of 2nd/3rd degree atrioventricular block 10. History of Reactive Airways Disease (RAD) 11. Any condition which would make the participant, in the opinion of the investigator unsuitable for the study.

Study Design


Intervention

Drug:
0.25% Timolol Maleate Gel Forming Solution
50:50 Randomized 0.25% Timolol Maleate Gel Forming Solution
0.5% Timolol Maleate Gel Forming Solution
50:50 Randomized 0.5% Timolol Maleate Gel Forming Solution

Locations

Country Name City State
United States Johns Hopkins Medical Center Baltimore Maryland
United States Boston Children's Hospital Boston Massachusetts
United States Ann and Robert H. Lurie Children's Hospital of Chicago Chicago Illinois
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States The University of Texas Medical School at Houston Houston Texas
United States Indiana University Health Indianapolis Indiana
United States Dartmouth-Hitchcock Medical Center Lebanon New Hampshire
United States DCOL Center for Clinical Research Longview Texas
United States Medical College of Wisconsin Milwaukee Wisconsin
United States Columbia University Medical Center New York New York
United States Children's Hospital of Philadephia Philadelphia Pennsylvania
United States Mayo Clinic Rochester Minnesota

Sponsors (3)

Lead Sponsor Collaborator
Kanecia Obie Zimmerman National Institutes of Health (NIH), The Emmes Company, LLC

Country where clinical trial is conducted

United States, 

References & Publications (1)

Drolet BA, Boakye-Agyeman F, Harper B, Holland K, Lewandowski A, Stefanko N, Melloni C; Pediatric Trials Network Steering Committee (See Acknowledgments for a listing of committee members.). Systemic timolol exposure following topical application to infantile hemangiomas. J Am Acad Dermatol. 2020 Mar;82(3):733-736. doi: 10.1016/j.jaad.2019.02.029. Epub 2019 Feb 18. No abstract available. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Pharmacokinetics (PK) Analysis Measuring Maximum Concentration of Timolol in Plasma Specimen The PK blood samples will be 1.0 ml each and collected between the following timeframes after application of Timolol: within 2 hours, 2-4 hours, 5-7 hours, 8-10 hours or 11-12 hours. Up to 12 hours
Other Pharmacokinetics (PK) Analysis Measuring Area Under the Curve of Timolol in Plasma Specimen The PK blood samples will be 1.0 ml each and collected between the following timeframes after application of Timolol: within 2 hours, 2-4 hours, 5-7 hours, 8-10 hours or 11-12 hours. Up to 12 hours
Other Pharmacokinetics (PK) Analysis Measuring Volume of Distribution of Timolol in Plasma Specimen The PK blood samples will be 1.0 ml each and collected between the following timeframes after application of Timolol: within 2 hours, 2-4 hours, 5-7 hours, 8-10 hours or 11-12 hours. Up to 12 hours
Other Pharmacokinetics (PK) Analysis Measuring Clearance of Timolol in Plasma Specimen The PK blood samples will be 1.0 ml each and collected between the following timeframes after application of Timolol: within 2 hours, 2-4 hours, 5-7 hours, 8-10 hours or 11-12 hours. Up to 12 hours
Primary Number of Participants With Partial Response of Hemangioma Volume as Measured by VAS (Visual Analog Scale) Within Each Treatment Arm and Compared With Untreated Controls The VAS-volume is a 100 mm scale used to independently grade hemangioma volume. -100 indicates hemangioma has doubled in size, 0 indicates no change, and +100 indicates complete shrinkage. Partial response is defined as >20% and up to 80% reduction in volumetric size of hemangioma. 180 days
Secondary Number of Participants With Partial Response in Hemangioma Color as Measured by VAS (Visual Analog Scale) Within Each Treatment Arm and Compared With Untreated Controls The VAS-color is a 100 mm scale used to independently grade hemangioma color. -100 indicates hemangioma is twice as intense, 0 indicates no change, and +100 indicates complete resolution. Partial response is defined as >30% and up to 80% reduction in color of hemangioma. 180 days
Secondary Number of Participants With Partial Response of Hemangioma Volume as Measured by VAS (Visual Analog Scale) Within Each Treatment Arm The VAS-volume is a 100 mm scale used to independently grade hemangioma volume. -100 indicates hemangioma has doubled in size, 0 indicates no change, and +100 indicates complete shrinkage. Partial response is defined as >20% and up to 80% reduction in volumetric size of hemangioma. 180 days
Secondary Comparison of Partial Response of Hemangioma Color From Baseline to 180 Days, Within Each Treatment Arm Comparison of partial response of hemangioma color (partial response or greater as assessed by VAS-color) between the two treatment arms. Partial response: >30% and up to 80% reduction in color of hemangioma. 180 days
Secondary Change in Hemangioma Dynamic Complication Scale (HDCS) Absolute change in hemangioma dynamic complication scale from Day 0 to end of study within each treatment arm. The HDCS provides a 6-point severity grading system for 12 individual hemangioma-related complications (grade 0 represents absent to minimal; grade 5 = most severe). The total score ranges from 0-60. baseline, day 180
Secondary Number of Participants Who Reach Partial Response, Assessed by Volume Assess time to partial response or greater by VAS-volume, comparing baseline to day 30, day 60, day 120 and day 180. Partial response: >20% and up to 80% reduction in volumetric size of hemangioma 30 days, 60 days, 120 days, 180 days
Secondary Number of Participants Who Reach Partial Response, Assessed by Hemangioma Color Assess time to partial response or greater by VAS-color, comparing baseline to day 30, day 60, day 120 and day 180. Partial response: >30% and up to 80% reduction in color of hemangioma 180 days
Secondary Change in Hemangioma Quality of Life (IH-QoL) Assessment for Infants Absolute change in IH-QoL score scale from Day 0 to end of study within each treatment arm. The IH-QoL score scale consists of 4 domains (physical symptom of patient, social functioning of patient, social and psychological functioning of caregiver, and emotional functioning of caregiver) and 29 items, with each item scored on a Likert scale : 0 = never a problem, 1 = almost never a problem, 2 = sometimes a problem, 3 = often a problem and 4 = almost always a problem). The total range is 0-116; the higher the total number indicates a worse outcome. baseline, day 180
Secondary Number of Serious Adverse Events and Adverse Events of Special Interest in Infants Treated With Topical Timolol Maleate Serious adverse events and adverse events of special interest from randomization to Day 180 in infants treated with topical timolol maleate (0.25% and 0.5%) GFS for the treatment of infantile hemangioma. up to 270 days
See also
  Status Clinical Trial Phase
Completed NCT02505971 - Nadolol Versus Propranolol in Children With Infantile Hemangiomas Phase 3
Recruiting NCT04288700 - Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma Phase 4
Completed NCT01431326 - Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Completed NCT01010308 - Nadolol for Proliferating Infantile Hemangiomas Phase 2
Completed NCT01673971 - Optical Tomographic Imaging of Infantile Hemangiomas
Recruiting NCT03237637 - Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas Phase 3
Recruiting NCT05479123 - Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas Phase 4
Terminated NCT01434849 - Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial) Phase 1
Completed NCT04105517 - Hemangiol, Post Marketing Surveillance Study
Completed NCT01512173 - Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo Phase 2
Completed NCT01056341 - Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy Phase 2/Phase 3
Not yet recruiting NCT04684667 - ''Efficacy of Propranolol in the Treatment of Infantile Hemangioma" Phase 2
Recruiting NCT03842631 - Optimizing Timolol Maleate Treatment of Infantile Hemangioma by Doppler Ultrasound Examination
Recruiting NCT03173352 - A Prospective Study on the Incidence and Related Risk Factors of Infantile Hemangioma in China N/A